Genmab — Januar 2017
-
Det lægger an til en grøn åbning generelt.

-
Darvin det tror jeg hellere ikke, jeg følger den blot, da jeg har købt en mindre portion for at afdække den lille risko som der er i retssagen, og det har indtil videre været en god investering, på røde dage falder den mindre end genmab, og på grønne stiger den mere end genmab.
-
-
1200
-
Mon ikke at alle med 3xBull kommer tørskoede i land inden luk af instrumentet.
-
-
Morphosys er foran Genmab i NHL. De har allerede en mor208-kombi i fase 3 mod DLBCL. https://www.clinicaltrials.gov/ct2/show/NCT02763319?term=mor208&rank=1
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind